These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32084321)

  • 1. Emerging Standards and Analytical Science for Nanoenabled Medical Products.
    Nelson BC; Minelli C; Doak SH; Roesslein M
    Annu Rev Anal Chem (Palo Alto Calif); 2020 Jun; 13(1):431-452. PubMed ID: 32084321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisation.
    Halamoda-Kenzaoui B; Vandebriel RJ; Howarth A; Siccardi M; David CAW; Liptrott NJ; Santin M; Borgos SE; Bremer-Hoffmann S; Caputo F
    J Control Release; 2021 Aug; 336():192-206. PubMed ID: 34126169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical nanotechnology: evolving appropriate risk tools.
    Moore R
    Med Device Technol; 2007 Sep; 18(5):36-7. PubMed ID: 17939370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars.
    Mühlebach S; Borchard G; Yildiz S
    Nanomedicine (Lond); 2015 Mar; 10(4):659-74. PubMed ID: 25723097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulating Nanomedicine at the Food and Drug Administration.
    Paradise J
    AMA J Ethics; 2019 Apr; 21(4):E347-355. PubMed ID: 31012422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of nanotechnology in medicine: treatment and diagnostics.
    Owen A; Dufès C; Moscatelli D; Mayes E; Lovell JF; Katti KV; Sokolov K; Mazza M; Fontaine O; Rannard S; Stone V
    Nanomedicine (Lond); 2014 Jul; 9(9):1291-4. PubMed ID: 25204820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric-flow field-flow fractionation for measuring particle size, drug loading and (in)stability of nanopharmaceuticals. The joint view of European Union Nanomedicine Characterization Laboratory and National Cancer Institute - Nanotechnology Characterization Laboratory.
    Caputo F; Mehn D; Clogston JD; Rösslein M; Prina-Mello A; Borgos SE; Gioria S; Calzolai L
    J Chromatogr A; 2021 Jan; 1635():461767. PubMed ID: 33310281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Science Approach in Pharmaceutical Development of Follow-on Versions of Non-Biological Complex Drug Products.
    Zagalo DM; Simões S; Sousa J
    J Pharm Sci; 2022 Oct; 111(10):2687-2713. PubMed ID: 35901943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.
    Paliwal R; Kumar P; Chaurasiya A; Kenwat R; Katke S; Paliwal SR
    Curr Pharm Des; 2022; 28(2):165-177. PubMed ID: 34781869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Status of Nanomaterial Medical Device and Discussion on Biological Evaluation].
    Sun L; Wan M; Sun X; Liu J; Gai X; Wang G; Ruan W; Qin Y; Liu C
    Zhongguo Yi Liao Qi Xie Za Zhi; 2024 Jan; 48(1):88-93. PubMed ID: 38384224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking temperature--a review of European Union regulation in nanomedicine.
    D'Silva J; van Calster G
    Eur J Health Law; 2009 Sep; 16(3):249-69. PubMed ID: 19788003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology in healthcare: are existing laws adequate?
    Munir AB; Yasin SH
    Eur J Health Law; 2007 Nov; 14(3):261-72. PubMed ID: 18229763
    [No Abstract]   [Full Text] [Related]  

  • 14. [Nanomedicine: application of nanotechnology in medicine. Opportunities in neuropsychiatry].
    Szebeni J
    Neuropsychopharmacol Hung; 2011 Mar; 13(1):15-24. PubMed ID: 21451188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology and nanomedicine: going small means aiming big.
    Teli MK; Mutalik S; Rajanikant GK
    Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research training and academic disciplines at the convergence of nanotechnology and biomedicine in the United States.
    Kim KY
    Nat Biotechnol; 2007 Mar; 25(3):359-61. PubMed ID: 17344886
    [No Abstract]   [Full Text] [Related]  

  • 18. Toward an international standardisation roadmap for nanomedicine.
    Caputo F; Favre G; Borchard G; Calzolai L; Fisicaro P; Frejafon E; Günday-Türeli N; Koltsov D; Minelli C; Nelson BC; Parot J; Prina-Mello A; Zou S; Ouf FX
    Drug Deliv Transl Res; 2024 Sep; 14(9):2578-2588. PubMed ID: 38865038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: introduction to nanotechnology: potential applications in physical medicine and rehabilitation.
    Agoramoorthy G; Chakraborty C
    Am J Phys Med Rehabil; 2007 Dec; 86(12):1031-2; author reply 1032. PubMed ID: 18090446
    [No Abstract]   [Full Text] [Related]  

  • 20. A Decision Support System for preclinical assessment of nanomaterials in medical products: the REFINE DSS.
    Zabeo A; Rosada F; Pizzol L; Caputo F; Borgos SE; Parot J; Geertsma RE; Pouw JJ; Vandebriel RJ; Moreno OI; Hristozov D
    Drug Deliv Transl Res; 2022 Sep; 12(9):2101-2113. PubMed ID: 35538190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.